Comparison

SARCULATOR vs CARTOX

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

SARCULATOR

This medical tool provides physicians with predictive models for retroperitoneal and extremity sarcoma patients. It estimates overall survival and disease-free survival, serving as an informative resource to enhance physician predictive capabilities.

Highlights
  • Predictive models for sarcoma patients
  • Estimates 5-year overall survival
  • Estimates 5-year disease-free survival
  • Estimates 10-year overall survival
  • Estimates cumulative incidence of distant metastasis
  • Informative tool for physicians
Features
Read full description

This app is meant to be used only by physicians and it is not meant to make clinical decisions (the clinical usefulness of the two models has not been tested) but to be used as an informative tool to improve the predictive capability of a physician. Two kinds of predictions are possible: - RPS: 5-year overall survival (OS) and 5-year disease-free survival (DFS) in primary resected retroperitoneal sarcoma (RPS) patients. . - ESTS: 5- and 10-year overall survival (OS) and cumulative incidence of distant metastasis (CCI of DM) in primary resected extremity STS patients.

About

CARTOX

This medical app aids clinicians in assessing and managing toxicities associated with cellular therapies, including Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). It provides grading methods and treatment recommendations for healthcare professionals caring for patients undergoing immune effector cell therapy.

Highlights
  • Toxicity grading
  • CRS assessment
  • ICANS assessment
  • Treatment recommendations
  • Antimicrobial prophylaxis guidance
Features
Read full description

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.

Screenshots

SARCULATOR4 screens
CARTOX4 screens

Verdict

The call

The clearest difference is rating: CARTOX at 5.0 against SARCULATOR's 4.3. SARCULATOR's advantage is update cadence (every 6 months vs every 20 months) and iOS requirement (15.0 vs 26.4). On price, ratings volume, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

CARTOX holds the better App Store score, 5.0 against 4.3. Both are backed by a comparable volume of ratings — 3 and 6 respectively.

UpkeepUpdate frequency

SARCULATOR ships an update every 6 months, CARTOX every 20 months. The most recent releases landed on November 19, 2026 and November 18, 2026 respectively.

Scorecard3 real differences · 7 level
SARCULATOR versus CARTOX: the parameters behind the verdict, then further details
ParameterSARCULATORCARTOX
PriceFreeFree
Rating4.3 (3 ratings)5.0 (6 ratings) — better
Positive reviews—100.0% of reviews
Number of ratings36 — better
Update frequencyEvery 6 months — betterEvery 20 months
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPad, iPod — betteriPhone, iPad
Requires iOS15.0 — better26.4
Further details — not scored
Size29 MB6 MB
Age rating12+17+
DeveloperDIGITAL FOREST SRLMD Anderson Cancer Center

Customer experience

SARCULATOR

All ratings3 ratings
Positive66.7%
Neutral33.3%
Negative0.0%

CARTOX

All ratings6 ratings
Positive100.0%
Neutral0.0%
Negative0.0%
Written reviews1 reviews
Positive100.0%
Neutral0.0%
Negative0.0%

In-app purchases

None

SARCULATOR

No in-app purchases

None

CARTOX

No in-app purchases

Questions

Is SARCULATOR free?
SARCULATOR is free to download, with no in-app purchases.
Is CARTOX free?
CARTOX is free to download, with no in-app purchases.
Which has better reviews, SARCULATOR or CARTOX?
CARTOX is rated higher. SARCULATOR averages 4.3 out of 5 from 3 ratings, while CARTOX averages 5.0 from 6 ratings.
Do SARCULATOR or CARTOX have ads?
Neither SARCULATOR nor CARTOX shows ads.
Which is updated more often, SARCULATOR or CARTOX?
SARCULATOR ships an update every 6 months, and CARTOX every 20 months. Most recently, SARCULATOR was updated on November 19, 2026 and CARTOX on November 18, 2026.

Other comparisons